FDA Releases Updated COVID-19 Vaccine Guidelines
The new guidelines contain formulation recommendations for vaccines launching in autumn 2023.
FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) met on June 15, 2023 to discuss and make recommendations for updated COVID-19 vaccines for use in the United States in autumn of 2023. The committee unanimously voted that the vaccine composition be updated to a monovalent COVID-19 vaccine with an XBB-lineage of the Omicron variant.
At the meeting, VRBPAC reviewed available data on the circulation of various SARS-CoV-2 virus variants, current vaccine effectiveness, human immunogenicity data of current vaccines against recently circulating virus variants, the antigenic characterization of circulating virus variants, animal immunogenicity data generated by new candidate vaccines expression or containing updated spike components, and preliminary human immunogenicity data generated by one XBB.1.5 vaccine candidate. The committee was also informed of current manufacturing timelines.
Based on the provided evidence, FDA ultimately advised manufacturers planning to update their COVID-19 vaccines that they should develop vaccines with a monovalent XBB.1.5 composition. FDA plans to continue monitoring the safety and effectiveness of the COVID-19 vaccines and the evolution of the SARS-CoV-2 virus.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
